← Oncology Approval Tracker

FDA DECISION ·

Jaypirca

pirtobrutinib · Eli Lilly

Accelerated approvalNew or expanded indicationCLL / SLL
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Dec 2, 2025

FDA Project Confirm ↗

APPROVED USE

What FDA approved

For adults with CLL or SLL after two or more treatment lines that included both a BTK inhibitor and a BCL-2 inhibitor.

LAMPGEN ANALYSIS

Why it matters

The accelerated approval added a noncovalent BTK inhibitor for patients exposed to both required classes.

What research teams should watch

Record individual prior lines and drug classes, and track the indication's confirmatory milestone.

PRIMARY RECORDS

Sources